The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects

British Journal of Clinical Pharmacology

Volumn 62, Issue 6, 2006, Pages 682-689

  Pedersen, Rasmus S ^a   Damkier, Per ^b   Brosen, Kim ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

CYP2C8 polymorphisms; Drug interaction; Fluvoxamine; Pharmacokinetics; Rosiglitazone

Indexed keywords

CYTOCHROME P450 2C8; DRUG METABOLITE; FLUVOXAMINE MALEATE; ROSIGLITAZONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GENOTYPE; GEOMETRY; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BLOOD GLUCOSE; DRUG INTERACTIONS; FEMALE; FLUVOXAMINE; GENOTYPE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PHARMACOGENETICS; THIAZOLIDINEDIONES;

EID: 33750994952     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02706.x     Document Type: Article

References (41)

1. Patel J, Miller E, Patwardhan R. Rosiglitazone (BRL49653) monotherapy has significant glucose lowering effect in type 2 diabetic patients. Diabetes 1998; 47: A17.
2. Patel J, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab 1999; 1: 165-72.
3. Young PW, Buckle DR, Cantello BCC, Chapman H, Clapham JC, Coyle PJ, Haigh D, Hindley RM, Holder JC, Kallender H, Latter AJ, Lawrie KWM, Mossakowska D, Murphy GJ, Cox LR, Smith S. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther 1998; 284: 751-9.
4. Cox PJ, Ryan DA, Hollis FJ, Harris AM, Miller AK, Vousden M, Cowley H. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos 2000; 28: 772-80.
5. Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 1999; 48: 424-32.
6. Wang JS, Neuvonen M, Wen X, Backman JT, Neuvonen PJ. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos 2002; 30: 1352-6.
7. Wen X, Wang JS, Backman JT, Kivisto KT, Neuvonen PJ. Gemfibrozil is a potent inhibitor of human cytochrome P4502C9. Drug Metab Dispos 2001; 29: 1359-61.
8. Niemi M, Backman JT, Granfors M, Laitila J, Neuvonen M, Neuvonen PJ. Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia 2003; 46: 1319-23.
9. Niemi M, Backman JT, Neuvonen PJ. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P4502C8 substrate rosiglitazone. Clin Pharmacol Ther 2004; 76: 239-49.
10. Park JY, Kim KA, Shin JG, Lee KY. Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects. Br J Clin Pharmacol 2004; 58: 397-402.
11. Park JY, Kim KA, Kang MH, Kim SL, Shin JG. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin Pharmacol Ther 2004; 75: 157-62.
12. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW. Selective biotransformation of taxol to 6-alpha-hydroxytaxol by human cytochrome-P450 2C8. Cancer Res 1994; 54: 5543-6.
13. Li XQ, Bjorkman A, Andersson TB, Ridderstrom M, Masimirembwa CM. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8. A new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther 2002; 300: 399-407.
14. Klose TS, Blaisdell JA, Goldstein JA. Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Mol Toxicol 1999; 13: 289-95.
15. Bahadur N, Leathart JBS, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, Van Houdt J, Hendrickx J, Mannens G, Bohets H, Williams FM, Armstrong M, Crespi CL, Daly AK. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6 alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 2002; 64: 1579-89.
16. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, Goldstein JA. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001; 11: 597-607.
17. Hichiya H, Tanaka-Kagawa T, Soyama A, Jinno H, Koyano S, Katori N, Matsushima E, Uchiyama S, Tokunaga H, Kimura H, Minami N, Katoh M, Sugai K, Goto Y, Tamura T, Yamamoto N, Ohe Y, Kunitoh H, Nokihara H, Yoshida T, Minami H, Saijo N, Ando M, Ozawa S, Saito Y, Sawada J. Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population. Drug Metab Dispos 2005; 33: 630-6.
18. Totah RA, Rettie AE. Cytochrome P4502C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 2005; 77: 341-52.
19. Bidstrup TB, Damkier P, Olsen AK, Ekblom M, Karlsson A, Brosen K. The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide. Br J Clin Pharmacol 2006; 61: 49-57.
20. Niemi M, Leathart JB, Neuvorten A, Backman JT, Daly AK, Neuvonen PJ. Polymorphism in CYP2C8 is associated with the reduced plasma concentrations of repaglinide. Clin Pharmacol Ther 2003; 74: 380-7.
21. Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, Eichelbaum M, Kivisto KT, Neuvonen PJ. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 2005; 77: 468-78.
22. Martinez C, Garcia-Martin E, Blanco G, Gamito FJG, Ladero JM, Agundez JAG. The effect of the cytochrome P450CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. Br J Clin Pharmacol 2005; 59: 62-9.
23. Garcia-Martin E, Martinez C, Tabares B, Frias J, Agundez JAG. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P4502C8 and 2C9 amino acid polymorphisms. Clin Pharmacol Ther 2004; 76: 119-27.
24. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52: 349-55.
25. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 525-38.
26. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalyzed by the R144C allelic variant of Cyp2C9. Pharmacogenetics 1994; 4: 39-42.
27. SullivanKlose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA. The role of the CYP2C9-Leu (359) allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6: 341-9.
28. Lee CR, Goldstein JA, Pieper JA. Cytochrome P4502C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12: 251-63.
29. Schoch GA, Yano JK, Wester MR, Griffin KJ, Stout CD, Johnson EF. Structure of human microsomal cytochrome P4502C8 - evidence for a peripheral fatty acid binding site. J Biol Chem 2004; 279: 9497-503.
30. Williams PA, Cosme J, Ward A, Angova HC, Vinkovic DM, Jhoti H. Crystal structure of human cytochrome P4502C9 with bound warfarin. Nature 2003; 424: 464-8.
31. Yasar U, Lundgren S, Eliasson E, Bennet A, Wiman B, de Faire U, Rane A. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun 2002; 299: 25-8.
32. Hemeryck A, De Vriendt C, Belpaire FM. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes. Eur J Clin Pharmacol 1999; 54: 947-51.
33. Jeppesen U, Rasmussen BB, Brosen K. Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. Clin Pharmacol Ther 1997; 62: 279-86.
34. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brosen K. Dose dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996; 51: 73-8.
35. Madsen H, Enggaard TP, Hansen LL, Klitgaard NA, Brosen K. Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. Clin Pharmacol Ther 2001; 69: 41-7.
36. Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome-P4501A2. Biochem Pharmacol 1993; 45: 1211-4.
37. Walsky RL, Gaman EA, Obach RS. Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 2005; 45: 68-78.
38. Pedersen RS, Verstuyft C, Becquemont L, Jaillon P, Brosen K. Cytochrome P4502C9 (CYP2C9) genotypes in a Nordic population in Demmark. Basic Clin Pharmacol Toxicol 2004; 94: 151-2.
39. Verstuyft C, Morin S, Yang J, Loriot MA, Barbu V, Kerb R, Brinkmann U, Beaune P, Jaillon P, Becquemont L. Rapid and robust genotyping strategy for cytochrome P4502C9 and MDR1 single nucleotide polymorphism identification. Ann Biol Clin 2003; 61: 305-9.
40. Pedersen RS, Brosen K, Nielsen F. HPLC method for determination of rosiglitazone in plasma. Chromatographia 2005; 62: 197-201.
41. Kerdpin O, Elliot DJ, Boye SL, Birkett DJ, Yoovathaworm K, Miners JO. Differential contribution of active site residues in substrate recognition sites 1 and 5 to cytochrome p450 2C8 substrate selectivity and regioselectivity. Biochem 2004; 43: 7834-42.